31 January 2018 - - As part of its CareCentered Contracting program, US-based pharmacy benefit manager (PBM) Prime Therapeutics LLC recently entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, the company said.
As a PBM owned by 18 Blue Cross and Blue Shield plans, Prime is positioned to analyze both medical and pharmacy claims data to evaluate and manage total cost of care.
Prime looks at members' experiences holistically and this CareCentered Contracting agreement will focus on the total cost of care for members taking Jardiance and comparing that to the total cost of care for patients taking other diabetic medications.
In this manner, Prime can evaluate the combined cost of pharmacy and medical on select therapies and its impact on overall health costs for members.
Prime Therapeutics manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid.
The company processes claims and offers clinical services for people with complex medical conditions. Serving more than 20 million people, Prime is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries, or affiliates of those plans.